Request Deal Involvement

Abingworth, Bain Capital Life Sciences, and Venrock Healthcare led a $180m Series A round in Timberlyne Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

or

Principals

VENROCK HEALTHCARE CAPITAL PARTNERS

bidder

VENROCK HEALTHCARE CAPITAL PARTNERS

LILLY ASIA VENTURES

bidder

LILLY ASIA VENTURES

BRAIDWELL LP

bidder

BRAIDWELL LP

ABINGWORTH MANAGEMENT

bidder

ABINGWORTH MANAGEMENT

BOYU CAPITAL

bidder

BOYU CAPITAL

TIMBERLYNE THERAPEUTICS

target

TIMBERLYNE THERAPEUTICS

BAIN CAPITAL LIFE SCIENCES

bidder

BAIN CAPITAL LIFE SCIENCES

3H HEALTH INVESTMENT

bidder

3H HEALTH INVESTMENT

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Abingworth, Bain Capital Life Sciences, and Venrock Healthcare led a $180m Series A round in Timberlyne Therapeutics.